ENTR-701

Vertex pays Entrada $224M for preclinical rare disease drug, opening new front in assault on dystrophy
Fierce Biotech
Thu, 12/8/22 - 10:35 am
Vertex Pharmaceuticals
Entrada Therapeutics
ENTR-701
myotonic muscular dystrophy